Intelligence desk

Products

Signal Tracker Data Platform Data Enrichment API

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Inhibrx Biosciences, Inc. logo — Innovation Focused Outcomes Driven

Inhibrx Biosciences, Inc.

Innovation Focused Outcomes Driven

Founded 2010 United States San Diego, United States 111 employees Post Ipo Equity Total: $269.59M Biotechnology, Health and Wellness +1

General Information

Company Name Inhibrx Biosciences, Inc.
Founded Year 2010
Location United States San Diego, United States +1
Founders / Decision Makers
Klaus W. Wagner — CMO
Employees 111
Industries Biotechnology, Health and Wellness, Life Sciences
Funding Stage Post Ipo Equity
Social

Get notified when Inhibrx Biosciences, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Inhibrx Biosciences, Inc.

Inhibrx, Inc. is a biotechnology startup founded in 2010 with a mission to provide optimized, biologic therapeutics for individuals facing life-threatening conditions. The company's diverse pipeline, based on single domain antibody platform technology, shows potential in addressing cancer and orphan diseases. Inhibrx's single domain antibodies offer a modular and versatile approach to target binding, enabling the creation of therapeutic candidates tailored to the biology of specific antigens. The innovative sdAb-based formats have various functions, including receptor clustering, engaging multiple antigens or epitopes, synergistic functions, and tissue-specific therapeutic activity. Most notably, the startup received a significant $200.00M Post-IPO Equity investment on 29 August 2023 from RA Capital Management, Perceptive Advisors, TCG Crossover, and Viking Global Investors. This ample investment showcases the confidence of these prominent investors in Inhibrx's innovative approach and potential impact in the biotechnology industry. In conclusion, Inhibrx, Inc. stands out in the biotechnology sector with its emphasis on innovation and outcomes. The recent substantial investment further solidifies its position for potential growth and future achievements.

Taxonomy: biologic therapeutics, single domain antibodies, cancer treatment, orphan diseases, clinical-stage biotechnology, oncology, infectious diseases, protein engineering, target biology, multispecific therapeutic formats, collaborations, NIH, NIAID, CARB-X

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity $200.00M 4
RA Capital Management Perceptive Advisors TCG Crossover Viking Global Investors
29 Aug 2023
Convertible Note $40.00M 6
Lilly Asia Ventures RA Capital Management ArrowMark Partners Viking Global Investors WuXi
Alexandria 		21 May 2019
Venture Round $3.55M - 11 May 2018
Grant $6.04M - 31 Dec 2017
Debt Financing $20.00M - 09 Apr 2015

Inhibrx Biosciences, Inc. Alternatives & Competitors

Inhibrx Biosciences, Inc. vs
Rubedo Life Sciences
Rubedo Life Sciences United States

Medicines to keep you biologically young by targeting the pathological cells that drive chronic dise...

Series A
32 employees
Biotechnology, Health Care
Inhibrx Biosciences, Inc. vs
Sevion Therapeutics
Sevion Therapeutics

Pioneering groundbreaking therapies for cancer and immunological diseases with innovative antibody t...

Post Ipo Equity
Biopharma, Biotechnology
Inhibrx Biosciences, Inc. vs
SQZ Biotechnologies
SQZ Biotechnologies United States

Unlocking the full potential of cell therapies for patients around the world

Grant
18 employees
Biotechnology, Health and Wellness

FAQ About Inhibrx Biosciences, Inc.

Innovation Focused Outcomes Driven
Inhibrx Biosciences, Inc. was founded in 2010.
Inhibrx Biosciences, Inc. is headquartered in San Diego, United States.
Inhibrx Biosciences, Inc. operates in the following industries: Biotechnology, Health and Wellness, Life Sciences.
Inhibrx Biosciences, Inc. has approximately 111 employees.
Inhibrx Biosciences, Inc. has completed 5 funding rounds, raising a total of $269.59M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Inhibrx Biosciences, Inc. include Rubedo Life Sciences, Sevion Therapeutics, SQZ Biotechnologies, Dice Therapeutics, Ritter Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Inhibrx Biosciences, Inc. and Rubedo Life Sciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Inhibrx Biosciences, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy